CRIS vs. SGMO, SABS, XFOR, AGEN, ALVR, BLUE, PLX, VIGL, ATRA, and PASG
Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Sangamo Therapeutics (SGMO), SAB Biotherapeutics (SABS), X4 Pharmaceuticals (XFOR), Agenus (AGEN), AlloVir (ALVR), bluebird bio (BLUE), Protalix BioTherapeutics (PLX), Vigil Neuroscience (VIGL), Atara Biotherapeutics (ATRA), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.
Curis received 246 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Curis an outperform vote while only 62.66% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, indicating that its stock price is 259% more volatile than the S&P 500.
Sangamo Therapeutics presently has a consensus target price of $5.67, suggesting a potential upside of 952.50%. Curis has a consensus target price of $37.33, suggesting a potential upside of 126.67%. Given Curis' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Curis.
In the previous week, Curis had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Curis and 2 mentions for Sangamo Therapeutics. Curis' average media sentiment score of 0.23 beat Sangamo Therapeutics' score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Curis has lower revenue, but higher earnings than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sangamo Therapeutics has a net margin of -146.30% compared to Sangamo Therapeutics' net margin of -473.04%. Curis' return on equity of -82.17% beat Sangamo Therapeutics' return on equity.
Summary
Curis beats Sangamo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Curis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
